We propose that targeting ANXA1 may offer a strategy to suppress COL1A1-positive oncostreams in GBM, possibly with enhanced selectivity compared to targeting collagen 1 directly (since ANXA1 is less abundant in the normal brain than COL1A1). The gene discussed is ANXA1; the disease is glioblastoma.